Pulse Biosciences, Inc (NASDAQ:PLSE) CTO Sells $246,000.00 in Stock

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report) CTO Darrin Uecker sold 15,000 shares of the firm's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $16.40, for a total transaction of $246,000.00. Following the transaction, the chief technology officer now directly owns 137,872 shares in the company, valued at $2,261,100.80. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pulse Biosciences Stock Up 0.1%

Shares of NASDAQ PLSE traded up $0.01 during trading on Thursday, reaching $15.05. 238,550 shares of the stock traded hands, compared to its average volume of 186,989. Pulse Biosciences, Inc has a 52-week low of $9.70 and a 52-week high of $25.00. The company has a 50-day moving average of $16.98 and a 200-day moving average of $17.79.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Pulse Biosciences

Several large investors have recently modified their holdings of PLSE. Vanguard Group Inc. lifted its stake in shares of Pulse Biosciences by 15.1% during the 4th quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after buying an additional 150,506 shares in the last quarter. Bank of America Corp DE grew its stake in Pulse Biosciences by 0.4% in the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after buying an additional 2,884 shares in the last quarter. Geode Capital Management LLC raised its holdings in Pulse Biosciences by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 460,768 shares of the company's stock valued at $8,024,000 after acquiring an additional 3,603 shares during the period. Invesco Ltd. lifted its position in shares of Pulse Biosciences by 1,956.7% during the fourth quarter. Invesco Ltd. now owns 214,490 shares of the company's stock worth $3,734,000 after acquiring an additional 204,061 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Pulse Biosciences by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after acquiring an additional 1,092 shares in the last quarter. Hedge funds and other institutional investors own 76.95% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen upgraded Pulse Biosciences to a "sell" rating in a report on Monday, March 31st.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.